



Fourth International Congress on Platelet-activating Factor and Related Lipid Mediators

September 22-26, 1992

C.V.R.T.I., BUILDING-500 □ UNIVERSITY OF UTAH □ SALT LAKE CITY, UT 84112
PHONE (801) 581-8183 □ FAX (801) 581-3128

CHAIRMAN

STEPHEN M. PRESCOTT

CO-CHAIRMAN

THOMAS M. MCINTYRE

GUY A. ZIMMERMAN

University of Utah

USA ADVISORY COMMITTEE

GIORA Z. FEUERSTEIN

SmithKline Beecham

DONALD J. HANAHAN

University of Texas (San Antonio)

SAN-BAO HWANG

Merck Sharp & Dohme

JOHN M. JOHNSTON

University of Texas (Dallas)

MERLE S. OLSON

University of Texas (San Antonio)

FRED L. SNYDER

Oak Ridge Associated Universities

ROBERT L. WYKLE

Bowman Gray School of Medicine

INTERNATIONAL

ADVISORY COMMITTEE

MARCO BAGGIOLINI

University of Bern, Switzerland

PETER J. BARNES

University of London, Great Britain

WOLFGANG E. BERDEL

Free University of Berlin, Germany

PIERRE BRAQUET

Institut Henri Beaufour, France

GIOVANNI CAMUSI

University of Naples, Italy

GIANFRANCESCO GORACCI

University of Perugia, Italy

KUE-HSIUNG HSIEH

National Taiwan University, Taiwan

KEIZO INOUE

University of Tokyo, Japan

SOHEI MAKINO

Dokkyo University, Japan

SANTOSH NIGAM

Free University of Berlin, Germany

SHOSHICHI NOJIMA

Teikyo University, Japan

CHRIS O'NEILL

Royal North Shore Hospital, Australia

CLIVE PAGE

King's College London, Great Britain

KUNIHICO SAITO

Kansai Medical University, Japan

MARIANO SANCHEZ CRESPO

Fundacion Jimenez Diaz (Madrid), Spain

HENK VAN DEN BOSCH

University of Utrecht, The Netherlands

B. BORIS VARGAFTIG

Pasteur Institute (Paris), France

JOHN L. WALLACE

University of Calgary, Canada

Wednesday, August 28, 1991

Harmon C. McAllister, Ph.D.

Research Director

The Council for Tobacco

Research-U.S.A., Inc.


900 Third Avenue

New York, N.Y. 10022

Dear Dr. McAllister:

I am writing to solicit your support for the *Fourth International Congress on Platelet-activating Factor and Related Lipid Mediators*. PAF is a phospholipid with diverse, potent effects. It has been implicated in a variety of allergic and inflammatory disorders and in cardiovascular disease including thrombosis, vascular injury, and, perhaps, atherosclerosis. Certain physiological events, in particular those associated with reproductive biology, also have been shown to involve PAF metabolism. This series of congresses was initiated to bring together researchers from various disciplines to present the latest information on this interesting compound, its synthesis and degradation, and its biological effects. Various aspects of its biochemistry, analytical chemistry, pharmacology, and clinical applications are covered in other meetings. However, this is the only forum that is able to attract individuals from diverse disciplines. The previous congresses have been held in Paris (1983), Gatlinburg, Tennessee (1986), and Tokyo (1989). The next one will be held from September 22-26, 1992 at Snowbird, Utah, near Salt Lake City. This time was chosen because a number of advances in the understanding of the biochemistry and molecular biology of the synthetic and degradative enzymes and the receptor for PAF are likely to be available by 1992. Additionally, several clinical trials of receptor antagonists should have been completed. The fall was picked because it is a time of year when excellent facilities are available at a reasonable cost.

I hope that you can provide financial support for this meeting. This congress is operated as an independent, free-standing meeting without the benefit of society sponsorship. Based on previous congresses, we anticipate attendance of 400 to 500 scientists from throughout the world. They will include basic scientists




and clinicians, from both academic institutions and industrial laboratories. They use a broad range of scientific instruments, reagents and pharmaceuticals. We have established several principles to guide our planning of the congress. One of these is to establish a fee structure that will allow trainees - students and postdoctoral fellows - to attend the meeting. A reduced rate for them obviously will mean a deficit in our operating expenses in other areas. Additionally, we need to raise funds beyond the registration fee to allow us to help support the travel of scientists from abroad who will present their work at the congress.

The congress will run for three days and will include both plenary and simultaneous sessions for oral presentations, as well as poster sessions. The plenary sessions and simultaneous sessions will consist of presentations by invited speakers and by individuals selected from submitted abstracts. There will be sessions on biochemistry, molecular biology, pharmacology, medicinal chemistry, analytical methods, animal models and physiology, and clinical trials. Additionally, we will have sessions on lipids related to PAF including other lipids with ether bonds, which have been implicated as antitumor agents and important in the regulation of growth control, and oxidatively fragmented phospholipids that have been implicated as having related effects to PAF. The final structure of the program, the decision to issue invitations to various speakers, and the selection of oral presentations from submitted abstracts will be decided by the advisory committees.

I would be happy to answer questions that you may have or discuss with you the availability of sponsorship of certain events (e.g. social functions, such as the banquet or coffee breaks, travel support for specific areas of interest). Additionally, some space will be available for displays by corporate sponsors. Contributions should be addressed to the Fourth International Congress on PAF, care of me at the address shown. Thank you for your consideration of this request.

Sincerely yours,



Stephen M. Prescott, M.D.
*Professor of Internal Medicine
and Biochemistry
Chairman, Organizing Committee*